A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the ...

Sarepta has acquired the global rights to develop ARO-DUX4 and ARO-DM1, two RNAi therapeutic candidates for types of muscular ...

In preclinical studies, investigational ARO-ALK7 silenced Activin receptor-like kinase 7 (ALK7) expression in adipose tissue, which led to reduced body ...

Arrowhead (ARWR) announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-ALK7, the ...

Sirius Therapeutics today announced that preliminary data from its Phase 1 clinical trial of SRSD107, a next generation siRNA ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: ...

In the assessment of 12-month price targets, analysts unveil insights for Voyager Therapeutics, presenting an average target ...

Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after ...

GEN highlights six AI-based drug discoverers worthy of note based on pipeline or platform progress, and in one instance, a ...

In a study published in Cell Reports Physical Science on Nov. 25, a research team led by Prof. CAI Lintao from the Shenzhen ...

LMU researchers have investigated how cationic polymers organize on a molecular level when transporting RNA drugs.